NCT05053165View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

April 1, 2022

Study Completion Date

June 29, 2022

Conditions
Rheumatoid ArthritisNon-Alcoholic Steatohepatitis
Interventions
DRUG

LB-P6

Healthy subjects will be randomized to receive LB-P6 once daily orally

DRUG

LB-P8

Healthy subjects will be randomized to receive LB-P8 once daily orally

DRUG

Placebo

Healthy subjects will be randomized to receive placebo once daily orally

Trial Locations (1)

5000

Cmax Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

LISCure Biosciences

INDUSTRY